The DSTYK Knockout HCT 116 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt DSTYK gene function in the HCT 116 colorectal carcinoma cell line. This loss-of-function model provides a valuable tool for dissecting the molecular mechanisms regulated by DSTYK, a dual-specificity kinase implicated in apoptosis, necroptosis, and autophagy. The polyclonal nature of the knockout pool allows for the study of heterogeneous genetic modifications, reflecting diverse mutational outcomes typical of CRISPR/Cas9-mediated editing. By abrogating DSTYK expression, researchers can examine its impact on downstream signaling pathways and cellular processes critical to cancer biology.
The HCT 116 host cell line is a well-characterized epithelial colorectal carcinoma model derived from a male patient. It harbors a KRAS G13D mutation, rendering it constitutively active in the MAPK/ERK signaling cascade, and exhibits a near-diploid karyotype, which simplifies genetic analyses. HCT 116 is extensively employed in colorectal cancer research for investigating tumorigenesis, drug sensitivity, and signal transduction. Its robust growth characteristics and amenability to genetic manipulation make it an ideal platform for generating knockout models to probe gene function in a disease-relevant context.
DSTYK encodes a dual serine/threonine and tyrosine kinase that integrates signals from tumor necrosis factor alpha (TNF-??), CD95 ligand, and growth factors to modulate cell fate decisions. Mechanistically, DSTYK interacts with RIPK1 and BECN1, thereby regulating necroptosis via RIPK1-RIPK3-MLKL and autophagy via the BECN1-ATG5-ATG12 complex. It also influences the MAPK/ERK pathway by promoting ERK1/2 phosphorylation. Through these interactions, DSTYK functions as a critical node, balancing survival, necroptotic death, and autophagic flux in response to environmental cues. Disruption of DSTYK therefore perturbs key signaling hubs, enabling detailed dissection of its regulatory roles.
In the HCT 116 context, DSTYK knockout is particularly significant given the cell line??s KRAS-driven ERK activation, which converges with DSTYK??s modulatory functions. This model allows exploration of crosstalk between oncogenic RAS/ERK signaling and cell death pathways, shedding light on how cancer cells evade apoptosis and necroptosis. It is highly relevant for colorectal cancer, where DSTYK may contribute to tumor progression and drug resistance. Additionally, DSTYK mutations are linked to congenital anomalies of the kidney and urinary tract (CAKUT) and neurological disorders, broadening the model??s utility for studying kinase-dependent developmental processes.
Researchers can employ these polyclonal knockout cells in a panel of assays, including western blotting and RT-qPCR to confirm DSTYK disruption and assess downstream effectors like ERK1/2 and MLKL; flow cytometry with Annexin V/PI for apoptosis quantification; LC3 turnover assays to measure autophagy flux; and transwell migration/invasion studies to evaluate metastatic potential. Cell viability assays and phospho-ERK analysis further elucidate functional consequences in signaling networks. This product is ideally suited for probing cell death pathway crosstalk, autophagy regulation, and kinase-targeted drug responses in colorectal cancer. For further details, please contact Ascent Research.
